Novel Bio is expanding our team in Vancouver, WA! We are currently looking for a talented Research Associate with molecular biology experience to join our team to help enable the next wave of genetic medicines. Take a look: https://lnkd.in/g7HuaDE4
Novel Biotechnology Inc.
Biotechnology Research
Woodbridge, Ontario 1,476 followers
Novel Biologics is a Canada based Biotechnology company focused on providing high quality plasmid DNA to its clients.
About us
Novel Biotechnology is a Synthetic Biology company focused on developing highly productive pDNA manufacturing platform. We also provide CRDMO and plasmid DNA manufacturing services to our clients.
- Website
-
http://www.novelbiologics.com
External link for Novel Biotechnology Inc.
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Woodbridge, Ontario
- Type
- Privately Held
- Founded
- 2021
Locations
-
Primary
81 Zenway Blvd
Woodbridge, Ontario L4H 0S5, CA
Employees at Novel Biotechnology Inc.
-
Monika Gupta
MSc Biotechnology, PhD Biochemistry
-
Santhosh Thomas Kallivalappil
Co-Founder and Executive Director of Research & Development. at Novel Biotechnology Inc.
-
Matthew Weinstock
Dedicated Biotech Scientist | Inventor | Educator | Leader | Executive | Advisor
-
Michelle Slind
Associate Scientist, Synthetic Biology | Program Management | Operations Development
Updates
-
We are very happy to welcome Nicholas Smith, PhD to the team at Novel Bio! Nick will be leading our Bioservices Team and will oversee our partnered programs and commercial workflows for plasmid DNA production. Welcome to the team!
-
Check out this post by our CTO Matthew Weinstock, where he comments on a resent study shining a light on the disturbing reality of plasmid DNA quality. This is a major issue for the industry! At Novel Biotechnology Inc., we address this issue and differentiate ourselves from other plasmid manufacturers in two ways: First, we have proprietary plasmid manufacturing technologies that perform significantly better than the industry standard E. coli platforms used by everyone else. This means we produce higher quality material, especially when it comes to difficult plasmids such as ITR-containing AAV vectors and large, self-amplifying RNA plasmids. Our technologies allow us to overcome the recombination events and low plasmid yield/quality issues that are common with other providers. Second, we perform extensive quality control on all plasmids that we produce. We have access to multiple sequencing platforms to enable us to sequence every base pair of a plasmid to confirm that the sequence we produce matches the desired sequence at every position. If you are frustrated or concerned when it comes to plasmid, we'd love to share how we can help streamline and accelerate your research!
Does the integrity of your plasmid DNA keep you up at night? If not, maybe it should. A recent Nature article highlights results from a large-scale study on plasmid integrity, and the results are not good. The study examined 1000s of plasmids from labs around the world and uncovered a shocking result – most plasmids have design flaws or undetected sequence errors that are likely contributing to unexpected experimental failures. The study notes several common issues with plasmids: First, poor plasmid design on the part of the experimenter compromises plasmid functionality (like failing to add a stop codon to a gene). Second, the physical sequence of the plasmid does not match the corresponding electronic sequence map. These errors are due the outdated technology that many labs use to produce their plasmids coupled with poor quality control. With a subset of plasmids subjected to sequencing in the study, the authors found that only 65% of provided plasmids matched their electronic plasmid map (meaning that 35% of plasmids either contained undesired mutations or were actually completely different plasmids than expected). Shockingly, when they examined plasmids used for gene therapy applications, they found that 36% of plasmids had mutations in one of the two ITR regions (sequences that play a critical role in the functionality of viral-based gene therapies), meaning that these plasmids will likely not function as intended. The authors concluded that “In total, we estimate that 45-50% of lab-made plasmids have undetected design and/or sequence errors that could potentially compromise the intended applications.” They further conclude that “The high error rate of lab-made plasmids suggests that many labs lack the sophisticated and nuanced expertise needed to properly design vectors and furthermore, there is insufficient quality control of the plasmids being constructed and propagated in labs.” Serving as CTO at a company developing new tech for plasmid manufacturing, I can tell you these results are not surprising, nor are they only a problem in academic labs. At Novel Biotechnology Inc., we perform extensive quality control on all the plasmids we work with, including plasmids that we receive from clients and outside vendors where undetected mutations are extremely common. In one extreme case, we analyzed a plasmid manufactured by another vendor for one of our clients and found that it was highly contaminated with multiple other plasmids which our client had never worked with – meaning the vendor had sent them a plasmid prep that was a mix of other customers’ plasmids! This not only compromised the experiments our client had planned, but given the highly proprietary nature of plasmid designs, could seriously compromise the IP position of those other companies! This wasn’t a small, unknown vendor either. This is a serious conversation that needs to be had, especially as genetic medicines rise in prominence.
Serious errors plague DNA tool that’s a workhorse of biology
nature.com
-
Are you concerned about sending your DNA sequences overseas? Novel Bio is a North American Organization with labs in US and Canada. With our highly efficient NBx platform, we can handle difficult constructs with ease and our white glove service further enhances the customer experience. If you are struggling with your plasmid supplier, reach out to us!
US lawmakers ask FBI for briefing on GenScript Biotech's links to China
reuters.com
-
Novel’s team is growing. If sourcing plasmid DNA is an issue for you, reach out to us!
New Business Development & Strategic Alliance Management // delivering innovation against customer needs
I’m happy to share that I’m starting a new position as VP, Business Development & Alliance Management at Novel Biotechnology Inc.! Novel Bio’s plasmid DNA platforms are solving an innovation gap in modern medicine. While genetic medicines are the future, the critical fuel for their success is plasmid DNA, which has relied mostly on legacy technologies stuck in the past. Our platform is high yielding in less time with better quality & enabling new designs & medicines. I’m excited to be part of a talented team with a transformative technology!!
This content isn’t available here
Access this content and more in the LinkedIn app
-
We are excited to welcome Melissa Patterson PhD as VP of Business Development & Alliance Management!
New Business Development & Strategic Alliance Management // delivering innovation against customer needs
I’m happy to share that I’m starting a new position as VP, Business Development & Alliance Management at Novel Biotechnology Inc.! Novel Bio’s plasmid DNA platforms are solving an innovation gap in modern medicine. While genetic medicines are the future, the critical fuel for their success is plasmid DNA, which has relied mostly on legacy technologies stuck in the past. Our platform is high yielding in less time with better quality & enabling new designs & medicines. I’m excited to be part of a talented team with a transformative technology!!
This content isn’t available here
Access this content and more in the LinkedIn app
-
Do you need successful gene synthesis? At Novel we use the latest technological advances to assemble your most difficult genes. Take a look at this poster review of how our suppliers are performing and how the use of enzymatic DNA synthesis from Ansa Bio has helped us achieve 100% success in gene synthesis for our customers! #genesynthesis #ansabio #novelbio #plasmidprep https://lnkd.in/g2uAhnRv
-
2024 Continues to bring biotech layoffs as outlined by the Fierce Bio Layoff Tracker. Often this mean doing more with less resources and turning to external suppliers is often needed! #NovelBio strives to satisfy that need in #genesynthesis, #plasmidprep and #analytical services. In addition to offering our ground breaking NBx Platform, we work hard to provide premium service levels in the #synbio space. Novel Bio is different in that we vow the following: - We boast 100% success in gene synthesis to date using latest technologies - Ability to make complex sequence motifs like ITRs, UTRs, Poly A tails, etc. - Offering easy custom vector onboarding - Communicating along the way allowing you to seamlessly plan downstream efforts - Plasmid prep up to 50mg and/or storage capabilities for future use - Reasonable Price - Reasonable Delivery Speed - Perhaps most importantly...doing what we say we are going to do, when we say we are going to do it! https://lnkd.in/dtDZyvFi
Fierce Biotech Layoff Tracker 2024: Bayer cuts hit Basel; Tome lays off 131 staffers
fiercebiotech.com
-
We are hiring both in Canada and US. please spread the word
We are gearing up to expand our scientific team in both Winnipeg, MB and Portland, OR. Please spread the word! Winnipeg, MB job post: https://lnkd.in/gdDhQw96 Portland, OR post: https://lnkd.in/gSQsrBwi
Scientist Research and Development - Winnipeg, MB - Indeed.com
ca.indeed.com
-
We are gearing up to expand our scientific team in both Winnipeg, MB and Portland, OR. Please spread the word! Winnipeg, MB job post: https://lnkd.in/gdDhQw96 Portland, OR post: https://lnkd.in/gSQsrBwi
Scientist Research and Development - Winnipeg, MB - Indeed.com
ca.indeed.com